Patients with non-remission POD1GH levels were younger (p = 0.003) and had larger tumor diameter (p < 0.001), higher GH (p < 0.001), and lower FT3 (p < 0.001), TT3 (p = 0.004), TSH (p = 0.002), FSH (p < 0.001), and LH (p = 0.002) levels (Table 3). This evidence concerns the gene BRD2 and neoplasm.